Results of SAKK 06/14 trial with VPM1002BC as treatment for non-muscle-invasive bladder cancer have been published in European Urology Oncology
The phase I/II clinical trial data with VPM1002BC, a genetically modified bacillus Calmette-Guérin (BCG) strain, has been published in European Urology Oncology. Even three years after the treatment start, almost half of the patients remained recurrence-free. We thank all patients, colleagues, and collaborators for their contributions. Please click here to read the publication.